Express Scripts (ESRX) Guides 2017 EPS In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
Express Scripts Holding Company Announces 2017 Financial Guidance
December 14, 2016 7:00 AM ESTST. LOUIS, Dec. 14, 2016 /PRNewswire/ --Â Express Scripts Holding Company (Nasdaq: ESRX) anticipates achieving adjusted earnings per diluted share1 for 2017 in the range of $6.82 to $7.02, representing growth of 7% to 10% from the midpoint of our 2016 adjusted EPS guidance range.Â
"Our value proposition is clear; our opportunities to help patients and payers contain healthcare costs and improve clinical outcomes have never been greater," said Tim Wentworth, CEO and President. "As we continue to evolve our technological capabilities, expand the reach of our pharmacies, and enhance our patient experience, we... More
